SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Czene K) srt2:(2020-2022)"

Sökning: WFRF:(Czene K) > (2020-2022)

  • Resultat 31-40 av 61
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
31.
  •  
32.
  •  
33.
  •  
34.
  •  
35.
  •  
36.
  •  
37.
  • Eriksson, M, et al. (författare)
  • Reply to T. Suemasu et al
  • 2021
  • Ingår i: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. - 1527-7755. ; 39:26, s. 2966-
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
38.
  •  
39.
  • Eriksson, M, et al. (författare)
  • Use of Low-Dose Tamoxifen to Increase Mammographic Screening Sensitivity in Premenopausal Women
  • 2021
  • Ingår i: Cancers. - : MDPI AG. - 2072-6694. ; 13:2
  • Tidskriftsartikel (refereegranskat)abstract
    • Increased breast density decreases mammographic sensitivity due to masking of cancers by dense tissue. Tamoxifen exposure reduces mammographic density and, therefore, should improve screening sensitivity. We modelled how low-dose tamoxifen exposure could be used to increase mammographic sensitivity. Mammographic sensitivity was calculated using the KARMA prospective screening cohort. Two models were fitted to estimate screening sensitivity and detected tumor size based on baseline mammographic density. BI-RADS-dependent sensitivity was estimated. The results of the 2.5 mg tamoxifen arm of the KARISMA trial were used to define expected changes in mammographic density after six months exposure and to predict changes in mammographic screening sensitivity and detected tumor size. Rates of interval cancers and detection of invasive tumors were estimated for women with mammographic density relative decreases by 10–50%. In all, 517 cancers in premenopausal women were diagnosed in KARMA: 287 (56%) screen-detected and 230 (44%) interval cancers. Screening sensitivities prior to tamoxifen, were 76%, 69%, 53%, and 46% for BI-RADS density categories A, B, C, and D, respectively. After exposure to tamoxifen, modelled screening sensitivities were estimated to increase by 0% (p = 0.35), 2% (p < 0.01), 5% (p < 0.01), and 5% (p < 0.01), respectively. An estimated relative density decrease by ≥20% resulted in an estimated reduction of interval cancers by 24% (p < 0.01) and reduction in tumors >20 mm at detection by 4% (p < 0.01). Low-dose tamoxifen has the potential to increase mammographic screening sensitivity and thereby reduce the proportion of interval cancers and larger screen-detected cancers.
  •  
40.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 31-40 av 61

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy